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Josep Rodés-Cabau, MD, Rishi Puri, MBBS, PHDSEE PAGE 718A lthough transcatheter aortic valve replace-ment (TAVR) has evolved as a genuine thera-peutic option for patients with severe
symptomatic aortic stenosis, periprocedural stroke
rates still remain relatively high. In fact, of all
percutaneous cardiac interventions at the interven-
tional cardiologist’s disposal, TAVR is associated
with the highest stroke rate: averaging w3% within
the 30 days following the procedure in large registries
and hovering at 4% to 5% in the 2 randomized clinical
trials comparing TAVR and surgical aortic valve
replacement (SAVR) in high-risk patients (1–3).
Following a 10-year evolution in transcatheter valve
design and reﬁnements in procedural techniques,
stroke rates during TAVR have been relatively stag-
nant over time (4,5). In addition to the occurrence
of clinically-apparent stroke, several studies utilizing
serial brain magnetic resonance imaging (MRI) sys-
tematically demonstrated silent new cerebral lesions
in at least two-thirds of individuals undergoing
TAVR (3). Although these ﬁndings may, to some
extent, simply reﬂect the nature of TAVR in a high-
risk patient substrate with extensive comorbidities,
this may also reﬂect a fundamental limitation of
contemporary TAVR techniques. Yet, the quest for
TAVR to emerge as a viable alternative to SAVR in
lower-risk, younger patients with severe aortic steno-
sis is inevitable. Therefore, minimizing peri-TAVR
stroke risk to levels equivalent to or even lower*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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challenge.
A critical appraisal of the mechanisms associated
with cerebrovascular events during TAVR is impor-
tant for implementing effective measures to curb its
incidence. The multiple and diffuse distribution of
silent cerebral lesions evident on brain MRI post-
TAVR strongly suggests an embolic etiology (3).
Transcranial Doppler studies performed during TAVR
highlighted the occurrence of cerebral embolization
at virtually all time-points during the procedure, but
yet seem particularly frequent during valve posi-
tioning and implantation, suggesting an important
role of the mechanical interaction between trans-
catheter and native aortic valves (6). From a clinical
perspective, several studies found mechanical fac-
tors, such as balloon post-dilation, valve dislocation,
or embolization, or the need for a second valve each
associated with a higher cerebrovascular event rate
(7–9), particularly within the ﬁrst 24-h post-TAVR
period (7). Indeed, w50% of all 30-day cerebrovas-
cular events occurred after the ﬁrst 24-h post-
TAVR period, and these events appeared to be more
related to atrial arrhythmias and the underlying
systemic burden of atherosclerotic disease.With this background information in hand, in this
issue of JACC: Cardiovascular Interventions, Van Mie-
ghem et al. (10) present an extension of their prior
observations of the pathology of embolic debris
captured with the Montage Dual Filter embolic pro-
tection (Claret Medical, Inc., Santa Rosa, California)
during TAVR. After initially recruiting 40 patients, this
group previously demonstrated that embolic debris
was captured in 75% of TAVR cases, consisting of
ﬁbrin/thrombus, amorphous calcium, or connective
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726tissue (11). The authors subsequently enrolled
an additional 41 patients undergoing TAVR with
the Montage Dual Filter embolic protection system,
and they now present an expanded analysis aimed
at identifying patient and procedural factors asso-
ciated with cerebral embolization. Across 81 patients
undergoing TAVR using either a balloon or self-
expanding valve, embolic debris were ultimately
captured in 86% of the study population, ranging
in size from 0.1 to 9 mm. Thrombotic and tissue-
derived debris were retrieved in 74% and 63% of pa-
tients, respectively. The source of tissue embolizations
mostly ranged from native aortic valve leaﬂets, the
aortic wall, or left ventricular myocardium. Intrigu-
ingly, 10% of embolic fragments were deemed to be
foreign body-derived. The frequency of captured
debris was marginally greater in balloon- versus
self-expanding transcatheter valves; however, the rate
of captured thrombus did not differ according to valve
type. On multivariable logistic regression analysis, the
use of balloon-expandable valves and a greater cover
index (indicative of valve oversizing) were indepen-
dently associated with tissue embolization.
This analysis provides important mechanistic in-
sights that further illuminate the nature and reality of
TAVR-related cerebral embolization. First, the high
rate of captured debris is consistent with prior
transcranial Doppler and brain MRI studies, conﬁrm-
ing the seemingly inevitable occurrence of cerebral
emboli during TAVR. Second, the near systematic
presence of thrombus among the captured debris is
somewhat surprising and appeared to be more
frequent compared with other interventional pro-
cedures using ﬁlter devices (e.g., carotid stenting)
(12,13), highlighting the need to improve peri-TAVR
anticoagulation strategies. Consistent with this
notion were the suboptimal mean ACT levels (<250 to
300 s) reported by the authors, and future studies will
need to focus on identifying the optimal periproce-
dural anticoagulation strategy that associates with a
lower rate of thromboembolism. Furthermore, such a
high rate of thrombus within the ﬁlters raises the
question of whether thrombi could have been gener-
ated de novo within the ﬁlter. Third, tissue debris
were captured in about two-thirds of patients, which
conﬁrms the mechanical interaction between cathe-
ters, delivery systems, transcatheter valve, and the
vascular system as important contributory factors in
cerebral embolization during TAVR. Of note, tissue
debris not only were related to the aortic valve (valve
tissue, calciﬁc material), but also involved upstream
(aortic wall) and downstream (myocardium) struc-
tures, emphasizing once again the complexity of
the pathophysiology behind cerebral embolizationduring TAVR. Additionally, the authors found that a
balloon-expandable system and a greater degree of
valve oversizing increased the risk of tissue emboli.
Although these ﬁndings are novel and thought-
provoking, they should nevertheless be considered
hypothesis-generating due to some important caveats
(some of which have been acknowledged by the au-
thors). This single-center study was likely under-
powered to draw meaningful conclusions with
respect to the interaction between valve type and the
nature and frequency of debris (evidenced by
extremely wide conﬁdence intervals in multivariable
analyses). The ﬁnding of more frequent tissue
embolization with balloon- versus self-expanding
valves is at slight odds with a prior (similar-sized)
transcranial Doppler study, which suggested that
microemboli were more frequent during self-
expanding transcatheter valve implantation (6); it
also seems to be somewhat contradictory with larger-
scale clinical data showing no differences in stroke
rate between the 2 valve systems (14).
Furthermore, no differentiation was made between
the different origins of tissue debris, making it difﬁ-
cult to draw deﬁnitive conclusions regarding the
mechanisms behind the apparently higher tissue
emboli rate with balloon-expandable systems and a
higher degree of valve oversizing.
However, a number of clinical implications of
this study warrant consideration. The optimal peri-
procedural anticoagulation strategy during TAVR re-
mains empirical. The ubiquitous presence of captured
thrombus suggests the need for prospective evalua-
tions of various types and intensities of periproce-
dural anticoagulation strategies during TAVR. The
frequent nature of captured emboli also raises the
issue of whether embolic protection devices will ul-
timately ﬁnd a role during TAVR. Two pilot studies
with deﬂector devices (the Embrella Embolic
Deﬂector device [Edwards Lifesciences, Irvine, Cali-
fornia], and the TriGuard Embolic Deﬂection device
[Keystone Heart, Caesarea, Israel]) highlighted the
feasibility and safety of these systems during TAVR
(15,16). Although preliminary data showed a trend
toward a reduction of cerebral embolic lesion volume
with such devices, the number of new brain lesions
detected on brain MRI did not differ from historical
MRI data (15,16). However, the results of the pro-
spective randomized CLEAN-TAVI (Claret Embolic
Protection and TAVI) trial were recently presented
(17) showing the Montage Dual Filter embolic pro-
tection system’s ability to signiﬁcantly lower both the
volume and number of new brain lesions post-TAVR.
Importantly, early (day 2 post-TAVR) ataxia rates
were signiﬁcantly lower, favoring the group receiving
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727the embolic protection system. Another randomized
trial using this device and with surrogate brain MRI
endpoints is currently ongoing in the United States
(SENTINEL trial; NCT02214277).
The work by Van Mieghem et al. (10,11) represents a
step forward in understanding the burden and path-
ophysiology of cerebral emboli during TAVR and
would intuitively support the systematic use of
embolic protection devices during TAVR. However,
the utility of such devices as an adjunct during TAVR
will ultimately depend on their ability to lower
clinically-meaningful endpoints in a cost-effective
manner. The exceptionally high frequency of TAVR-
related cerebral embolism provides a unique oppor-
tunity to develop and standardize cerebral imaging
endpoints as a reliable surrogate biomarker of clinical
efﬁcacy. This would enable the medical community
to more readily conduct smaller-scale trials testing
novel devices, reﬁne procedural techniques, and
evaluate the effect of novel pharmacotherapeuticregimens at a lesser cost while exposing lesser
numbers of patients to a potentially inferior or futile
clinical strategy. This is the path that has been
followed to prove the efﬁcacy of embolic protection
devices in TAVR, with promising preliminary results.
If ultimately positive, surrogate cerebral imaging
data could then either result in direct imple-
mentation of such devices in routine clinical practice
or to inform the decision to invest in larger, pro-
spective, randomized clinical trials powered for clin-
ical endpoints. Meanwhile, we should continue to
investigate mechanisms underlying TAVR-related
cerebral embolism as a mandatory step in the pro-
cess of ultimately reducing TAVR-related cerebro-
vascular events.
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